TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01919164

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sprifermin
Description: Participants received Sprifermin as intra-articular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sprifermin
Description: Participants received Sprifermin as intra-articular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sprifermin
Description: Participants received Sprifermin as intra-articular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sprifermin
Description: Participants received Sprifermin as intra-articular injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received Placebo matched to sprifermin as intra-articular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants received Placebo matched to sprifermin as intra-articular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants received Placebo matched to sprifermin as intra-articular injection.
Study: NCT03454126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study: NCT03003910

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Best Possible Self
Description: Intervention group which requires people to envision themselves in a future in which all has gone in the best possible way.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Daily Activities
Description: Control group which consists of thinking and writing about all the activities and situations that had taken place during the last 24 h.
Study: NCT04355364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dornase Alfa Inhalation Solution [Pulmozyme]
Description: Administered by nebulization, at a dose of 2500 IU twice daily, 12 hours apart, for 7 consecutive days

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard procedure
Description: Patients will receive the usual care in accordance with good practice.
Study: NCT02564367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: 18 cycles S-1, orally administered twice daily D1-14, q 3 wks~S-1 starting dose: 2 x 30 mg/m\^2 body surface area (BSA), D1-14, q 3 wks First dose reduction: 2 x 25 mg/m\^2 BSA, D1-14, q 3 wks Second dose reduction: 2 x 20 mg/m\^2 BSA, D1-14, q 3 wks
Study: NCT00018824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NALTREXONE

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01684176

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Complex tailored intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Study: NCT01543568

Intervention type: DRUG
Group type: OTHER
Intervention: aflibercept 2.0 mg
Description: Intravitreal aflibercept injection 2.0 mg
Study: NCT04492423

Intervention type: DIAGNOSTIC_TEST
Intervention: VerifyNow PRUTest
Description: VerifyNow PRUTest for platelet aggregation

Intervention type: DIAGNOSTIC_TEST
Intervention: VerifyNow PRUTest
Description: VerifyNow PRUTest for platelet aggregation
Study: NCT02317991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab-paclitaxel 125 mg/m\^2 IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ramucirumab
Description: Ramucirumab 8 mg/kg IV
Study: NCT04378712

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrogen Oxygen Generator with Nebulizer
Description: Patients in treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) until discharge.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard-of-care
Description: Standard-of-care consisted of the supportive therapies (including oxygen therapy) recommended by the Chinese National Health Commission

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard-of-care
Description: Standard-of-care consisted of the supportive therapies (including oxygen therapy) recommended by the Chinese National Health Commission
Study: NCT02296489

Intervention type: DEVICE
Intervention: Capnostream20p
Description: The device will be used to monitor respiratory co2 values during the methacholine challenge, a well known diagnostic procedure

Intervention type: DEVICE
Intervention: Capnostream20p
Description: The device will be used to monitor respiratory co2 values during the methacholine challenge, a well known diagnostic procedure
Study: NCT03590171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Patients randomised to the HR-B arm receive induction, consolidation with the modified ALL R3 protocol. In this arm, patients are randomized to receive Bortezomib together with the ALL R3 protocol during induction. Administration of Bortezomib: 1.3 mg/m2 as intravenous bolus or subcutaneously (SC, at the discretion of the treating physician) on days 1 and 4 of weeks 1 and 3.
Study: NCT03714763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug treatment
Description: Subjects who show high expression of dopamine D2 receptors in PET-MR imaging will be treated with Cabergoline(CAB) tablets 2mg/week or bromocriptine(BC) tablets 7.5mg/ day.The pituitary hormone levels, tumor volume, visual acuity and visual field scale will be measured every 3 months. The medication will be stopped if failure to decrease tumor size and the subjects will be advised to surgical therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Subjects who show low expression of dopamine D2 receptors in PET-MR imaging will be treated with endoscopic transphenoidal pituitary surgery .
Study: NCT01429662

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Relaxation (MR)
Description: Modified Relaxation (MR) This technique intend to train participants in a group of 8-10 in only 1 session that lasts 60 minutes. After completing the training, participants will be given a hand-out on MR. They will be asked to practice MR at home once a day for 15-20 minutes during their leisure times, for at least 5 days a week during the whole 16 weeks of the study period.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Lifestyle Education (LE)
Description: Participants in this group will receive conventional care and lifestyle education on dietary choice and exercise.
Study: NCT02174107

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External radiotherapy
Description: The radiation technique used for each patient will be based on local clinical practices and on number of vertebae to treat between 1\*8 Gy; 5\*4 Gy and 10\*3 Gy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty
Study: NCT01321671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 330 mg, 600- 750 calorie
Description: A single oral dose of 330 mg controlled release tablet administered following a 600 to 750 calorie evening meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 330 mg, fasted
Description: A single oral dose of 330 mg controlled release tablet administered fasted in the evening

Intervention type: DRUG
Group type: OTHER
Intervention: Pregabalin immediate release, 300 mg
Description: A single oral dose of 300 mg immediate release capsule administered in the evening
Study: NCT02291029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFZ533 active - Cohort 1
Description: multiple doses of CFZ533 s.c. injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CFZ533 placebo- Cohort 1
Description: multiple doses of placebo s.c. injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFZ533 active - Cohort 2
Description: multiple doses of CFZ533 intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CFZ533 placebo - Cohort 2
Description: multiple doses of placebo intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFZ533 active -Cohort 3
Description: multiple doses of CFZ533 s.c. injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFZ533 active - Cohort 3
Description: Single dose of CFZ533 i.v. infusion and multiple doses of CFZ533 s.c. injection
Study: NCT01810224

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical revascularization
Description: The final intervention (surgical revascularization) will be the same for both arms.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical revascularization
Description: The final intervention (surgical revascularization) will be the same for both arms.
Study: NCT01051921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTS-1027
Description: CTS-1027 supplied in 5 and 10 mg tablets, 15 mg taken twice daily, for up to 48 weeks
Study: NCT03454126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study: NCT01051921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon
Description: Pegylated interferon, 180 micrograms in 0.5 ml of solution injected subcutaneously (SQ) once per week, for up to 48 weeks. Packaged in single use syringes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin, 200 mg capsules taken in two divided daily doses totaling 1000 mg (5 capsules) for patients weighing 75 kg or less, or 1200 mg (6 capsules) for patients weighing more than 75 kg for up to 48 weeks.
Study: NCT03160391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Training
Description: Training curriculums were developed using guidelines set by the Ontario Ministry of Education (The Ontario Curriculum, 2009) for teaching music to grades 1 to 3. Music was delineated into duration, pitch, dynamics and other expressive controls, timbre, texture/harmony, and form. training included direct instruction and group activities. All training programs had the same structure: a warm-up period, following by instruction from a teacher, and then group activities to practically demonstrate the concepts learned. Both programs involved working towards a variety of ensembles.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dance Training
Description: As with music training, dance was operationally defined by fundamental concepts for the art form, namely elements for body, space, time, energy, and relationship. The intervention involved both individual and group activities, with a combination of instruction and practical activities, and preparation for a final performance.
Study: NCT00377637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Description: Supplied as 500 mg tablets taken orally twice a day (BID). Dose specific for each arm. Dosing started at 500 mg BID for the first week, increasing by 500 mg in subsequent weeks until the final target dose was reached.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Description: Supplied as 500 mg tablets taken orally twice a day (BID). Dose specific for each arm. Dosing started at 500 mg BID for the first week, increasing by 500 mg in subsequent weeks until the final target dose was reached.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Intravenous cyclophosphamide (IVC) was administered every four weeks (monthly) to a total of six infusions.~Dosing was started at 0.75 g/m\^2 of body surface area for the first month, with subsequent doses at 0.5-1.0 g/m\^2. The target dose was 1.0 g/m\^2, but doses were titrated by 0.25 g/m\^2 increments to maintain nadir leukocyte count between 2500-4000/mm\^3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: 2 mg/kg/day orally, provided as 50 mg capsules to be taken after meals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Azathioprine
Description: Placebo capsules matching Azathioprine taken orally once a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Mycophenolate mofetil
Description: Placebo tablets matching Mycophenolate mofetil taken orally twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: Oral prednisolone (or equivalent) starting at a dose of 0.75-1.0 mg/kg/day (maximum 60 mg/day) tapered to 10 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: Oral prednisolone (or equivalent) starting at a dose of 0.75-1.0 mg/kg/day (maximum 60 mg/day) tapered to 10 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: Oral prednisolone (or equivalent) starting at a dose of 0.75-1.0 mg/kg/day (maximum 60 mg/day) tapered to 10 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: Oral prednisolone (or equivalent) starting at a dose of 0.75-1.0 mg/kg/day (maximum 60 mg/day) tapered to 10 mg/day.
Study: NCT01796028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: METFORMIN

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAXOTERE®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAXOTERE®
Study: NCT02076386

Intervention type: DRUG
Intervention: Dolutegravir
Description: Prospective, non-interventional study of the use of doluetegravir as part of an antiretroviral combination therapy in routine daily practice in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
Study: NCT03272243

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: short segment posterior spine fixation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: long segment posterior spine fixation
Study: NCT02063113

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Vulnerability and therapeutic changes in older patients with multiple myeloma.
Study: NCT04561648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractionated Heparin
Description: Before removing the introducer sheath, the 2nd operator will pass the missing UFH dose to the first operator to reach 100 IU per kg of body weight in a 10 ml syringe mixed with 0.9% saline solution. The blinded first operator will administer this without knowing if it is saline or the supplemental dose of unfractionated heparin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated Heparin
Description: Before removing the introducer sheath, the 2nd operator will pass the missing UFH dose to the first operator to reach 100 IU per kg of body weight in a 10 ml syringe mixed with 0.9% saline solution. The blinded first operator will administer this without knowing if it is saline or the supplemental dose of unfractionated heparin.
Study: NCT04536714

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pythagorean Self-Awareness Intervention program
Description: Stress management program of Pythagorean Self-Awareness Intervention (PSAI), which included eight sessions and lasted for eight weeks. On the first week, a personal session took place for measurements and training in the relaxation technique of diaphragmatic breathing. In the second week, patients attended a group session, in which they were adviced to follow specific directions for a healthy lifestyle, such as organized physical activity, adherence to the Mediterranean diet, creating a daily routine. In the third week, participants were introduced to the cognitive restructuring technique of (PSAI).In the following four group sessions, patients were trained on PSAI and the second relaxation technique, progressive muscular relaxation. In the last week, the final measurements were made. All sessions lasted for 120 minutes, except for the final one, which lasted for 60 minutes.
Study: NCT03028142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.5 mg RPL554 plus tiotropium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6 mg RPL554 plus tiotropium

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus tiotropium
Study: NCT02194972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pectin
Description: pectin （Andeli Ltd. Yantai, China）, 24g/d for 4weeks
Study: NCT02922153

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoanalgesia
Description: AtriCure® cryoICE cryo-ablation system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Institutional SOC for pain management will be followed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Institutional SOC for pain management will be followed.
Study: NCT03454126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study: NCT04395300

Intervention type: OTHER
Intervention: Web Based Survey
Description: On line survey distributed electronically
Study: NCT02555839

Intervention type: DRUG
Intervention: Pomalidomide
Description: 4mg capsule on d1 through 21 of a 28 day cycle

Intervention type: DRUG
Intervention: Dexamethasone
Description: 40 mg (≤75 years) or 20mg (\>75 years) oral on d1, 8, 15, 22 of a 28 day cycle

Intervention type: DRUG
Intervention: Pomalidomide
Description: 4mg capsule on d1 through 14 of a 21 day cycle

Intervention type: DRUG
Intervention: Dexamethasone
Description: cycle 1-8: 20mg PO (≤75 years) or 10mg (\>75years) on Days 1, 2, 4, 5, 8, 9, 11, 12 of a 21 day cycle; from cycle 9 onwards: Dexamethasone 20mg PO (≤75 years) or 10mg (\>75years) on Days 1, 2, 8, 9 of a 21 day cycle

Intervention type: DRUG
Intervention: Bortezomib
Description: cycle 1-8: Bortezomib (1,3mg/m2) s.c. on day 1, 4, 8, 11 of a 21 day cycle; from cycle 9 onwards: Bortezomib (1,3mg/m2) s.c. on day 1 and 8 of a 21 day cycle,
Study: NCT04177043

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HCV antibody and hepatitis B surface antigen (HBsAg) rapid diagnostic tests
Description: HCV antibody and hepatitis B surface antigen (HBsAg) rapid diagnostic tests

Intervention type: DRUG
Group type: OTHER
Intervention: DAAs
Description: Treatment with different regiments with DAAs
Study: NCT02580721

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dentsply Astra Tech Implant System EV
Description: Dentsply Astra Tech Implant System EV will be placed

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dentsply Astra Tech Implant System EV
Description: Dentsply Astra Tech Implant System EV will be placed
Study: NCT00327340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: custirsen (OGX-011)/mitoxantrone
Description: All subjects began treatment with oral prednisone (5 mg twice daily, 10 mg/day) continued through completion of the final treatment cycle. Three IV administrations of OGX-011 (640 mg) were given as 2 hr infusions during the loading dose period (Days-9 to-1). Subjects were premedicated with either ibuprofen (400 mg) or acetaminophen (650 mg) 30 to 60 minutes prior to and every 4-6 hours for 24 hours following each of the three doses of OGX-011 during the loading dose period only. After the loading dose period, OGX-011 was given weekly on Days 1, 8, and 15 of each 21-day cycle.~Mitoxantrone was administered IV on Day 1 of each cycle at a planned dose of 12 mg/m² infused over 30 minutes.~Patients could receive a maximum of 9 cycles of treatment.
Study: NCT02580721

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dentsply Astra Tech Implant System EV
Description: Dentsply Astra Tech Implant System EV will be placed

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dentsply Astra Tech Implant System EV
Description: Dentsply Astra Tech Implant System EV will be placed
Study: NCT03863873

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-Rich Plasma Injection Group
Description: Platelet-Rich Plasma Injection Group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-Rich Plasma Injection Group
Description: Platelet-Rich Plasma Injection Group
Study: NCT00464984

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle intervention
Description: Intensive lifestyle intervention at a rehabilitation centre 3 times a week the first 3 months of study

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle intervention
Description: Intensive lifestyle intervention at a rehabilitation centre 3 times a week the first 3 months of study
Study: NCT04538560

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: polar body biopsy
Description: Undergo polar body biopsy, and the NGS technology will be used to evaluate the polar body euploidy and then predict the euploidy of the oocyte. Embryo transfer priority according to the NGS test results and morphological scores.
Study: NCT04670289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TenoMiR (Low Dose)
Description: Mimic of miR29a
Study: NCT00327340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: custirsen (OGX-011)/docetaxel
Description: All subjects began treatment with oral prednisone (5 mg twice daily, 10 mg/day) continued through completion of the final treatment cycle. Three IV administrations of OGX-011 (640 mg) were given as 2 hr infusions during the loading dose period (Days-9 to -1). Subjects were premedicated with either ibuprofen (400 mg) or acetaminophen (650 mg) 30 to 60 minutes prior to and every 4-6 hours for 24 hours following each of the three doses of OGX-011 during the loading dose period only. After the loading dose period, OGX-011 was given weekly on Days 1, 8, and 15 of each 21 day cycle.~Docetaxel was administered IV on Day 1 of each cycle at a planned dose of 75 mg/m² infused over 60 minutes.~Patients could receive a maximum of 9 cycles of treatment.
Study: NCT04042571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebral oxymetry monitoring (NIRS)
Description: Near-InfraRed Spectroscopy (NIRS) is a non-invasive method measuring tissue oxygenation by regional saturation of capillary-oxygenated hemoglobin (rSO2). Starting on day 4 after aneurismal rupture NIRS electrods will be placed and maintained until day 12 permanently and blindly recording rSO2. Patients will be monitored following daily practice recommandations inclunding vasospasm detection and treatment.